Format

Send to

Choose Destination
Curr Med Chem. 2018 May 13. doi: 10.2174/0929867325666180514111500. [Epub ahead of print]

Perspectives and new aspects of metalloproteinases' inhibitors in therapy of CNS disorders: from chemistry to medicine.

Author information

1
Department of Medical Chemistry, Medical University of Lublin. Poland.
2
Department of Pharmacology and Pharmacodynamics, Medical University of Lublin. Poland.
3
Department of Pharmacognosy with Medicinal Plants Unit, Medical University of Lublin. Poland.

Abstract

Matrix metalloproteinases (MMPs) play a key role in remodelling of the extracellular matrix (ECM) and, at the same time, influence cell differentiation, migration, proliferation and survival. Their importance in variety of human diseases including cancer, rheumatoid arthritis, pulmonary emphysema and fibrotic disorders has been known for many years but special attention should be paid on the role of MMPs in the central nervous system (CNS) disorders. Till now, there are not many well documented physiological MMP target proteins in the brain and only some pathological ones. Numerous neurodegenerative diseases is a consequence or result in disturbed remodeling of brain ECM, therefore proper action of MMPs as well as control of their activity may play crucial roles in the development and the progress of these diseases. In present review we discuss the role of metalloproteinase inhibitors, from the well-known natural endogenous tissue inhibitors of metalloproteinases (TIMPs) through exogenous synthetic ones like (4-phenoxyphenylsulfonyl)methylthiirane (SB-3CT), tetracyclines, batimastat (BB-94) and FN-439. As the MMP-TIMP system has been well described in physiological development as well as in pathological conditions mainly in neoplasctic diseases, the knowledge about the enzymatic system in mammalian brain tissue remain still poorly understood in this context. Therefore, we focus on MMPs inhibition in the context of physiological function of adult brain as well as pathological conditions including neurodegenerative diseases, brain injuries and others.

KEYWORDS:

CNS disorders; MMPs inhibition; brain; metalloproteinases; neoplasctic diseases

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center